Pricing Log in Create free account
Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue
+268.4%
EPS
+73.8%
Free cash flow
+81.1%
Total debt
+0.27%

Quarter to September 2026, against a year earlier

112.52 3.76 +3.46%
Market cap
$23.9B
P/E
0.0×
Fwd P/E
−64.6×
Dividend yield
—
F-score
4/9
Altman Z
9.29
Beneish M
−1.90
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Insmed, Inc. 10-K filed Feb 19, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 7:01 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 20, 2025: 57 added · 29 removed · 109 modified; 3 with only figures updated; 8 moved without change

  1. Added · Business Overview

    We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.

194 more changes in this Item, word by word, in Powerpack.